NCT00063401 - Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions

Ovarian CancerPeritoneal NeoplasmsFallopian Tube Neoplasms

Interventions

BIOLOGICAL

Cetuximab:

400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles

DRUG

Paclitaxel

175 mg/m2 Day 1, six 21-day cycles

DRUG

Carboplatin

AUC = 6 Day1, six 21-day cycles

Trial Locations (2)

ImClone Investigational Site, New York

ImClone Investigational Site, Philadelphia